Verona Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:I9SA Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
18 Nov 24	Buy€31,505	David Ebsworth	Individual	2,500	€12.60
11 Nov 24	Sell€11,267	Mark Hahn	Individual	300	€37.56
11 Nov 24	Sell€11,267	David Zaccardelli	Individual	300	€37.56
06 Nov 24	Buy€184,856	Christina Ackermann	Individual	5,235	€35.31
06 Nov 24	Buy€175,999	David Ebsworth	Individual	4,920	€35.77
04 Nov 24	Sell€522,063	Mark Hahn	Individual	16,209	€32.24
04 Nov 24	Sell€568,237	David Zaccardelli	Individual	17,629	€32.27
25 Oct 24	Sell€585,720	David Zaccardelli	Individual	18,102	€32.36
25 Oct 24	Sell€584,671	Mark Hahn	Individual	18,070	€32.36
22 Oct 24	Sell€2,130,529	Mark Hahn	Individual	525,768	€4.06
22 Oct 24	Sell€2,083,793	David Zaccardelli	Individual	514,152	€4.06
11 Sep 24	Sell€2,047,155	Mark Hahn	Individual	600,000	€3.41
11 Sep 24	Sell€2,047,373	David Zaccardelli	Individual	600,000	€3.41
13 Aug 24	Sell€1,164,441	Mark Hahn	Individual	49,800	€23.74
12 Aug 24	Buy€94,486	David Ebsworth	Individual	4,500	€21.00
12 Aug 24	Sell€4,580	Mark Hahn	Individual	200	€22.90
12 Aug 24	Sell€4,580	David Zaccardelli	Individual	200	€22.90
03 May 24	Sell€65,939	Kathleen Rickard	Individual	4,531	€14.55

Insider Trading Volume

Insider Buying: I9SA insiders have sold more shares than they have bought in the past 3 months.

Ownership Breakdown

What is the ownership structure of I9SA?
Owner Type	Number of Shares	Ownership Percentage
General Public	2,417,846	2.95%
Individual Insiders	3,662,871	4.48%
Hedge Funds	4,215,973	5.15%
VC/PE Firms	18,096,325	22.1%
Institutions	53,438,154	65.3%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 74.81% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
7.72%	Perceptive Advisors LLC	6,315,933	€235.4m	160%	5.26%
7.57%	RA Capital Management, L.P.	6,195,639	€230.9m	-29.7%	2.92%
6.82%	New Enterprise Associates, Inc.	5,584,753	€208.1m	0%	9.52%
5.15%	Maverick Capital, Ltd.	4,215,973	€157.1m	36.3%	2.88%
4.62%	OrbiMed Advisors LLC	3,777,778	€140.8m	0%	1.96%
4.34%	Vivo Capital, LLC	3,549,779	€132.3m	-46.3%	11.23%
4.14%	Frazier Life Sciences Management, LP	3,383,950	€126.1m	2.1%	5.2%
3.89%	Deep Track Capital, LP	3,180,025	€118.5m	-20.5%	3.77%
2.96%	Eventide Asset Management, LLC	2,425,846	€90.4m	360%	1.55%
2.65%	Federated Hermes, Inc.	2,167,900	€80.8m	0.2%	0.2%
2.3%	Wellington Management Group LLP	1,878,632	€70.0m	19.6%	0.01%
2.24%	Octagon Capital Advisors LP	1,835,200	€68.4m	-3.17%	11.65%
2.13%	Jennison Associates LLC	1,740,886	€64.9m	54.3%	0.04%
1.86%	David Zaccardelli	1,525,294	€56.8m	-1.8%	no data
1.76%	Caligan Partners, LP	1,436,878	€53.6m	-22.1%	16.65%
1.75%	Hood River Capital Management LLC	1,433,934	€53.4m	35%	0.78%
1.72%	Mark Hahn	1,411,417	€52.6m	-1.94%	no data
1.63%	T. Rowe Price Group, Inc.	1,335,194	€49.8m	40.6%	no data
1.49%	Bellevue Asset Management AG	1,220,059	€45.5m	7.57%	0.55%
1.44%	Citadel Advisors LLC	1,178,022	€43.9m	1,050%	0.05%
1.43%	Federated Equity Management Company of Pennsylvania	1,173,600	€43.7m	0%	0.24%
1.36%	Aisling Capital Management LP	1,115,352	€41.6m	0%	16.83%
1.36%	Loomis Sayles & Company, L.P.	1,111,096	€41.4m	0%	0.05%
1.27%	Janus Henderson Group plc	1,042,795	€38.9m	-4.51%	0.02%
1.2%	Rice Hall James & Associates, LLC	985,076	€36.7m	4.84%	1.95%